Clinical Utility of Clopidogrel Drug Response Testing
Clopidogrel (Plavix) is one of the most widely prescribed antiplatelet medications — used to prevent blood clots in patients with heart disease, stroke, and after coronary stent placement. Yet up to 30% of patients are “Clopidogrel non-responders” — meaning the drug provides little to no protection. The reason is almost entirely genetic.
The CYP2C19 Gene and Clopidogrel Response
Clopidogrel is a prodrug — it must be converted to its active form by the CYP2C19 enzyme in the liver. Variants in the CYP2C19 gene determine how efficiently this conversion occurs:
Poor metabolisers (CYP2C19 *2/*2, *2/*3): Cannot adequately activate Clopidogrel — at significantly higher risk of stent thrombosis and recurrent cardiovascular events. Approximately 2–5% of Europeans, 15% of East Asians, and 6–8% of Indians carry this genotype.
Intermediate metabolisers (*1/*2): Reduced Clopidogrel activation — moderately elevated cardiovascular risk. Approximately 25–30% of the population.
Normal metabolisers (*1/*1): Standard Clopidogrel response.
Rapid/Ultra-rapid metabolisers (*17 carriers): Enhanced activation — may have increased bleeding risk.
Clinical Implications
The FDA has issued a black box warning on Clopidogrel noting that poor metabolisers may not receive full therapeutic benefit. For these patients, alternative antiplatelet agents (Prasugrel, Ticagrelor) are recommended — and CYP2C19 genotyping is the only way to identify them before a cardiovascular event occurs.
Who Should Get CYP2C19 Testing?
Patients prescribed Clopidogrel after coronary stent placement (PCI)
Patients with a history of stroke or TIA on antiplatelet therapy
Patients with recurrent cardiovascular events despite Clopidogrel therapy
Anyone with a family history of poor drug response to antiplatelet medications
The Broader Case for Pharmacogenomics
Clopidogrel is just one example of how genetics determines drug response. Over 200 medications have pharmacogenomic guidance in their labels — covering antidepressants, statins, pain medications, anticoagulants, and more. Knowing your pharmacogenomic profile before prescribing can prevent adverse events and optimise treatment outcomes.
Know Your Drug Response Before Treatment Begins
MedicaMap by MapmyGenome uses your DNA to reveal how you metabolise 100+ medications — including cardiovascular drugs, antidepressants, statins, and pain medications — helping doctors prescribe the right drug at the right dose from the start.
